View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 10, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,753,631 shares, corresponding to 4.85% of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.00% (previously...

Sandvik AB: 1 director

A director at Sandvik AB sold 8,167 shares at 214.500SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the announcement in PDF Attachment

 PRESS RELEASE

Novonesis completes acquisition of dsm-firmenichs’s share of the Feed ...

Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

SKF AB: 1 director

A director at SKF AB bought 10,000 shares at 207.100SEK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
 PRESS RELEASE

Combining EVP roles of Human Health Biosolutions and Strategy & Integr...

Combining EVP roles of Human Health Biosolutions and Strategy & Integration As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration.  COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vi...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the announcement in PDF Attachment

ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
 PRESS RELEASE

Novonesis delivered a strong Q1 with 11% organic growth and confirms f...

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch